Sanam Pangali Sells 1,364 Shares of Alumis (NASDAQ:ALMS) Stock

Alumis Inc. (NASDAQ:ALMS) insider Sanam Pangali sold 1,364 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $35,968.68. Following the transaction, the insider directly owned 9,747 shares in the company, valued at approximately $257,028.39. The trade was a 12.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Sanam Pangali also recently made the following trade(s):

• On Monday, July 6th, Sanam Pangali sold 5,000 shares of Alumis stock. The stock was sold at an average price of $28.00, for a total value of $140,000.00.

Alumis Stock Performance

Shares of NASDAQ:ALMS opened at $27.80 on Friday. Alumis Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $31.35. The business has a 50-day simple moving average of $25.50 and a two-hundred day simple moving average of $25.25. The firm has a market cap of $3.54 billion, a price-to-earnings ratio of -14.04 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The company had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. As a group, research analysts predict that Alumis Inc. will post -2.87 earnings per share for the current year.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Institutional ownership has generally increased, including a significant expansion of Geode Capital Management’s position and additional buying by Goldman Sachs, Rhumbline Advisers and other investors. Such activity may provide some support for Alumis shares, although the reported purchases occurred in prior quarters.
• Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating on ALMS and maintained a $25 price target, suggesting the firm does not currently see a catalyst strong enough to support a more bullish outlook. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six insiders collectively sold 14,953 shares of Alumis at an average price of $26.37, generating approximately $394,311. Sellers included CFO John R. Schroer, whose position fell 11.72%, along with Mark Christopher Bradley, Jorn Drappa, David M. Goldstein, Roy C. Hardiman and Sanam Pangali. The transactions reduced individual holdings by roughly 1.28% to 12.28% and could weigh on investor sentiment because of the concentration of sales. However, insider sales can also reflect personal financial planning rather than a change in the company’s outlook. Alumis Insider Sale Filings
• Negative Sentiment: Alumis remains a clinical-stage biotechnology company with substantial losses. Its latest quarterly results missed both earnings and revenue expectations, while analysts forecast a full-year loss of approximately $2.87 per share. This limits fundamental support until the company reports meaningful clinical or development progress.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ALMS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. Wells Fargo & Company lifted their price objective on Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Guggenheim increased their target price on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, May 15th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $39.00 target price on shares of Alumis in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

Institutional Investors Weigh In On Alumis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank bought a new position in shares of Alumis during the 1st quarter valued at about $2,815,000. Elmind Capital LP purchased a new position in shares of Alumis during the first quarter valued at about $2,864,000. Stempoint Capital LP bought a new stake in shares of Alumis in the first quarter worth about $5,057,000. Janus Henderson Group PLC bought a new stake in shares of Alumis in the first quarter worth about $46,790,000. Finally, Spruce Street Capital LP purchased a new stake in shares of Alumis in the first quarter worth about $8,648,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.